Healthy
Conditions
Brief summary
Allogenic differentiated adipocytes (ANT-adip-AL) is produced by well-established techniques including cell harvesting from lipoaspirates obtained from healthy donors, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. This was an open-label study. Subjects were received subcutaneous injection of ANT-adip-AL and followed for 8 weeks according to the clinical trial protocol.
Interventions
BIOLOGICALRepaircell
allogenic differentiated adipocyte
Sponsors
Anterogen Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* male, 19 years of age or older * volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening * informed consent form signed
Exclusion criteria
* volunteers who have participated in other clinical studies related cell therapy within 30 days before this clinical trial * volunteers who received any immune-suppressive drug, corticosteroid or cytotoxic drug within the previous 30 days * volunteers who have tattoo or scar which disturb assessment of study at injection site * volunteers who have Creutzfeldt Jacobs disease or related disease or family history * volunteers who have allergy to bovine-derived materials * volunteers who have infectious disease such as hepatitis B virus (HBV), hepatitis C virus (HCV)and HIV * volunteers who have a symptom of septicemia or diagnosis of active Tuberculosis * volunteers who have a clinically relevant history of abuse of alcohol or drugs * volunteers who are considered not suitable for the study by investigator * volunteers who have history of surgery for malignant cancer in the past 5 years * volunteers who have congenital or acquired immunodeficiency syndrome * volunteers who have horrible anemia or thrombopenia * volunteers who have chronic disease such cardiovascular,renal and respirometer disease * volunteers who were immunosuppressed by disease (ex: chronic heart failure) * volunteers who were immunodepressed by treatment of medication * volunteers who is being treated with blood derivatives/who is going to get a blood derivatives * volunteers who have abnormal rage of CD4/CD8 ratio
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse events | week 8 | Evaluate the safety at week 8 whether any kind of Adverse event occurs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunological response II | week 8 | Infiltration of immune cells by histology based on five basic parameters: (0) No evidence of immune cell infiltration in all area of the tissue, (1) Slight immune cell infiltration visible in partial area of the tissue (barely visible), (2) Obvious immune cell infiltration visible in partial area of the tissue, (3) Slight immune cell infiltration visible in all area of the tissue, and (4) Intense immune cell infiltration visible in all areas of the tissue. |
| Immunological response I | change from baseline CD4/CD8 ratio at week 8 | CD4 (cluster of differentiation 4)/CD8 (cluster of differentiation 8) ratio |
Countries
South Korea
Outcome results
None listed